Incidence and impact of low-level viremia among people living with HIV who received protease inhibitor- or dolutegravir-based antiretroviral therapy

ObjectivesThe impact of very low-level viremia (VLLV) and (LLV) are rarely investigated among people living with HIV (PLWH) receiving dolutegravir- vs protease inhibitor (PI)-based antiretroviral therapy (ART).MethodsVirally suppressed PLWH long-term PI-containing ART were included in this study. The incidences developing VLLV (plasma RNA load (PVL) 20–49 copies/ml), LLV (PVL 50–999 virological failure (any PVL ≥ 1000 copies/ml) compared between those switched to dolutegravir-based remaining on ART.ResultsA total 183 regimens 309 remained regimens. 26.5 13.2 per 100 person-years follow-up the dolutegravir group, respectively, 17.1 7.0 PI group; there no statistically significant differences after adjusting for confounders. rate was 1.3 group 1.9 (p = 0.32). Neither nor related subsequent failure.ConclusionsAmong virally PLWH, risk or similar who continued PI-based therapy. not associated failure.